Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BlackBerry Trims Secure Communications Forecast as Precaution -- Market Talk

BlackBerry Trims Secure Communications Forecast as Precaution -- Market Talk

Dow JonesDow Jones2026/09/24 15:36

1136 ET - BlackBerry's cautious trim to its Secure Communications segment outlook is precautionary, says CEO John Giamatteo. BlackBerry revised its full-year revenue forecast for the segment to $260 million to $270 million and adjusted Ebitda outlook to be between $50 million and $58 million, down from $270 million to $280 million, and $57 million to $65 million, respectively. Giamatteo pointed to broader geopolitical uncertainty and U.S.-Canada trade tensions, noting that much of the segment relies on government contracts. "We just felt putting a little bit of caution into the forecast was the right thing to do versus surprising Wall Street," he says, but that "we haven't seen a material impact or lost deals." (adriano.marchese@wsj.com)

(END) Dow Jones Newswires

September 24, 2026 11:36 ET (15:36 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56